BioAdaptives, Inc. (OTC: BDPT) has outlined the scientific strategy behind its Xcellara cellular wellness platform ahead of the planned Aug. 1 commercial launch of XcellaraHeart. The platform combines a stem/progenitor cell mobilization base, supported by a human randomized controlled trial showing an average 268.8% increase in circulating stem/progenitor-type cells, with tissue-specific ingredients designed to support the body's natural signaling pathways and direct those cells to targeted areas.
XcellaraHeart, the platform's first commercial application, pairs the Xcellara base with Tanshinone IIA, a Danshen-derived compound studied for its role in cardiovascular SDF-1α/CXCR4 signaling. BioAdaptives said it plans to expand the platform with additional formulas targeting wellness categories including joint mobility, skin health, cognitive wellness and metabolic resilience using the same supply-and-direction development model.
The Xcellara base formula is the only dietary supplement with a human randomized, double-blind, placebo-controlled clinical trial demonstrating a 268.8% increase in circulating hematopoietic stem and progenitor cells at four weeks with zero adverse effects on more than twenty blood parameters. The Xcellara product line includes seven targeted formulas combining the clinically proven mobilization base with tissue-specific signaling ingredients for cardiac, joint, neural, dermal, longevity, and stress-resilience applications.
BioAdaptives is the developer of the Xcellara line of stem cell mobilization and tissue-homing supplements. The complete scientific evidence dossier for the XcellaraHeart formulation will be available at products.xcellara.com/science. The dossier separates what has been demonstrated in BioAdaptives’ human clinical research on the Xcellara base from published research on Tanshinone IIA and from the Company’s product-development rationale for combining the two.
This announcement matters because it highlights a novel approach in the dietary supplement industry: using clinically validated stem cell mobilization combined with targeted tissue-homing ingredients. For consumers, this could mean more effective supplements for cardiovascular health and other wellness areas. For the industry, it represents a shift towards evidence-based product development that may set new standards for efficacy claims.
The implications of this strategy extend beyond just one product. If successful, the Xcellara platform could be applied to multiple wellness categories, potentially offering a new paradigm for how supplements support the body’s natural repair processes. The company’s focus on transparency, with a public scientific dossier, also addresses growing consumer demand for evidence behind health products.
For more information, visit www.bioadaptives.com or the product site at products.xcellara.com.
